Virginia Economic Review

As the world continues to struggle with drug supply chains and critical shortages, clusters of activity have emerged to move the needle of medication affordability and accessibility.

John Newby is the CEO of Virginia Bio, the nonprofit statewide trade association that serves and promotes the life sciences industry in Virginia.

Eric Arocho is associate vice president at Eli Lilly and Company and the site lead on the company’s facility in Goochland County, announced last year.

The I95-I85 Intersection is anchored by the Tri-Cities of Petersburg (home to Civica Rx’s facility that produces a wide variety of affordable essential medicines), Hopewell, and Colonial Heights.

Pam Cheng is executive vice president of global operations and IT and chief sustainability officer at AstraZeneca, which recently announced a new facility in Albemarle County — the company’s first in Virginia.

Dave Maraldo is the senior vice president of Human Health Manufacturing Operations at Merck, one of the five largest biopharmaceutical companies in the world.

Merck’s expansion at its Rockingham County site, announced in late 2025, represents the continuation of a long, mutually beneficial tenure in the Commonwealth.

Best Medical International manufactures a crucial product that helps its users battle devastating cancers. Now, with an assist from VEDP, the company is getting its products into the hands of people who desperately need them.

A lot changed in Virginia’s life sciences industry in the space of about a month last fall. Between Sept. 16 and Oct. 20, biopharmaceutical manufacturing giants Eli Lilly and Company, AstraZeneca, and Merck & Co.

Recent major biopharmaceutical manufacturing announcements are positioning Virginia for a broader reshoring effort in the pharma industry. COVID-era supply chain disruptions and resulting shortages exposed the risks of over-reliance on overseas production for essential medicines.

Jenny Munson has surprised herself by launching not just one, but two businesses. Neither would have happened, the scientist believes, if she hadn’t moved her research program to Virginia Tech and the western Virginia city of Roanoke.

A pharmaceutical manufacturing innovation that came out of a Virginia university is changing the way medicines are made. The Commonwealth’s universities and the rest of its biopharma research community are making sure Virginia is ready to make the medicines of the future.

Would more men try to prevent unintended pregnancies if their choices for contraception went beyond a condom or vasectomy?

In October 2025, shovels went into the ground in Elkton, marking the start of a $3 billion pharmaceutical expansion project that will add 400,000 square feet to Merck’s existing campus.

Recent major biopharmaceutical announcements have sent a clear signal from the industry: Virginia is the future of biopharma manufacturing.

The Greater Richmond region is in the middle of the greatest population growth in its history.

When a naval ship is at sea, dozens of critical electronic systems onboard need to operate perfectly, or missions and lives could be in jeopardy. Those systems require consistent power to operate, but the power provided by the ship’s generators is often unreliable.

April Wade is executive director of the Virginia Nuclear Energy Consortium (VNEC), which represents stakeholders invested in research and development, workforce development, innovation, and advocacy for the nuclear energy industry.